Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds
NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer
Two-Point Rise In PSA Signals High-Risk Prostate Cancer
High Cervical Cancer Rates Indicate Access Problems
Lifestyle Changes Common After Cancer Diagnosis
Proton Beam Radiation Helps Cancer Patients Retain Vision
Cooperative Group Trials Approved By NCI Are Listed
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”